INTRODUCTION
Despite advances in pain medication and widely accepted guidelines for the treatment of pain such as the World Health Organization's analgesic ladder [1] , inadequate assessment and management of acute pain remains common in both the pre-hospital and Emergency Department (ED) setting, with pain prevalence figures of up to 90% in the ED [2, 3] and many patients undertreated [4] [5] [6] . Pain relief regimes work optimally when effective analgesics are supported by formal protocols/guidelines underpinned by staff and patient education [7] . The 'ideal analgesic' for acute pain should have rapid onset of action, act over an extended period of time, be well-tolerated and effective across a wide range of pain types in different populations.
Methoxyflurane belongs to the fluorinated hydrocarbon group of volatile anesthetics. It was first introduced as an inhalation anesthetic in the 1960s [8] , but its use was generally discontinued by the late 1970s due to availability of newer anesthetic agents and reports of dose-related renal tubular damage at anesthetic doses [9] [10] [11] . Among inhalational fluorinated anesthetics, methoxyflurane is unique in having well-documented analgesic properties at low doses [12] . It has been used extensively for over 30 years in Australia and New Zealand (administered via a handheld inhaler; Penthrox Ò , Medical Developments International Limited, Scoresby, Australia) as a self-administered, rapid-acting analgesic agent for short-term pain relief in emergency medicine, minor surgical and dental procedures. The Penthrox inhaler is a green whistle-shaped single-use device that delivers methoxyflurane in analgesic doses, with a maximum recommended dose in 24 h of two 3 mL vials [13] .
The historical concern regarding methoxyflurane has been nephrotoxicity, which was reported following significantly higher doses with deep methoxyflurane anesthesia [9] . Renal damage is most likely due to the metabolism of methoxyflurane in the liver and kidney and release of fluoride ions [14, 15] . Clinical experience suggests that a low but effective analgesic dose is not associated with the risk of renal adverse events [16] .
Laboratory evidence also shows a large safety margin for analgesic use of methoxyflurane in the Penthrox inhaler [a dose of 6 mL/day and settings [18] [19] [20] and for procedural analgesia [21] . Due to the physiochemical characteristics of methoxyflurane, absorption is rapid, providing fast onset of analgesic action (usually within 6-10 inhalations) to treat acute pain rapidly [13, 17] . The portability of the Penthrox inhaler and self-administration by the patient mean that it has practical advantages over alternatives such as nitrous oxide. Penthrox is a noncontrolled drug making it easier to prescribe and requiring less patient monitoring than opioid analgesics; it does not interfere with other analgesic agents or anesthetic drugs, and therefore does not limit subsequent treatment choices, and its effects are quickly reversible. Its characteristics make it suitable as a bridging analgesic, should more powerful intravenous (IV) analgesia be required, or for patients in whom IV access is difficult or impractical, or patients with contraindications or intolerance to other pain medications including opioids.
Penthrox may eliminate the need for opioid analgesia for dislocations or fractures, for example, since the pain relief from Penthrox with or without the addition of simple non-opioid analgesia, may be sufficient for reduction or splinting.
Despite a large volume of published literature supporting the efficacy and safety of methoxyflurane at analgesic concentrations [18] , previous studies have been mostly observational and uncontrolled. Furthermore, little data have been generated within an ED setting, or outside Australia and New Zealand. This double-blind, randomized, placebocontrolled, UK-based study evaluated the short-term efficacy and safety of methoxyflurane at low analgesic doses for the treatment of acute pain in patients presenting to the ED with minor trauma. The study included both adult and adolescent patients aged C12 years and the results for the full study population have been reported previously [22] . Since Penthrox has recently been approved in Europe for the treatment of adult patients, a subgroup analysis was performed to evaluate the data in patients aged C18 years, and the data for this adult subgroup are the focus of this secondary paper. contains an S-shaped polypropylene wick which absorbs the liquid methoxyflurane/normal saline, and a one-way valve that allows fresh air and methoxyflurane/normal saline vapor to be inhaled through the wick; and prevent expired air and moisture passing back through the wick. An activated carbon unit attached to the outlet of the inhaler minimizes the release of methoxyflurane in the vicinity of the patient.
METHODS

Study Design
Treatment randomization (using permuted block randomization), stratified by center and age group (adolescent/adult) was prepared by an independent statistician. At enrollment, each individual patient was allocated the next randomization number in the appropriate stratum. To prevent selection bias and maintain the blind, the assembling and dispensing of study medication was performed by an unblinded research team member, who loaded the inhalers and then placed each inhaler into a plastic bag, which was sealed, labeled with the patient randomization number and weighed. The patient and all other personnel involved with the conduct and interpretation of the study, including the investigators, site personnel and the study team, were blinded to the treatment allocation. The inhalers looked the same, but as methoxyflurane has a characteristic odor, one drop of methoxyflurane was placed on the outside of the primed inhaler before sealing the plastic bag so that the smell between active and placebo treatments was indistinguishable to the patient and treating physician upon opening.
The relative density of methoxyflurane (1.42) is greater than that of normal saline (1), therefore to maintain the blind in respect of inhaler weight, a larger volume of saline solution was contained in the placebo inhalers (5 mL) compared with the volume of methoxyflurane in the active inhalers (3 mL).
Patients were supplied with one Penthrox inhaler containing 3 mL of methoxyflurane or 5 mL placebo as soon as possible following enrollment and initial assessments, which was utilized as required. Study medication was self-administered by the patient by inhaling from the device, assisted where required by the research nurse. Each inhaler had a diluter hole at the mouthpiece end, which when covered with the patient's index finger, allowed the patient to inhale a higher concentration of study medication. A second inhaler containing 3 mL of methoxyflurane or 5 mL placebo was supplied if requested by the patient; no patient received a dose greater than 6 mL methoxyflurane (2 9 3 mL) or 10 mL placebo (2 9 5 mL). It was estimated that each inhaler could provide up to 1 h pain relief when used intermittently.
Following use, the inhaler(s) were weighed by the unblinded member of the research team to determine the dose of methoxyflurane or placebo inhaled by the patient.
To ensure that the placebo control study design was ethical and acceptable to patients and investigators, rescue medication was made available immediately upon request for all patients at any time during or after treatment with study medication, as recommended in the Committee for Medicinal Products for Human Use guideline CPMP/EWP/612/00 [23] and guidance from the Declaration of Helsinki on the use of placebo control. Rescue medications permitted while the patient was in the ED included IV, intranasal or oral opioids or paracetamol. At the time of discharge patients received 16 9 500 mg paracetamol tablets as rescue medication for the treatment of pain during the 14 ± 2 day follow-up period.
Efficacy Assessments
Pain intensity was measured using the Painlog TM (Schlenker Enterprises, Ltd., Lombard, IL, USA) 100 mm visual analog scale (VAS) before the first inhalation of study medication, at 5, 10, 15, 20 and 30 min after the start of study medication inhalation and every 30 min thereafter until rescue medication was administered or discharged from the ED, whichever was sooner. The pain VAS is frequently used in pain studies because it is easy to use, requires no verbal or reading skills, and is sufficiently versatile to be employed in a variety of settings [24, 25] .
The time point at which the patient first reported pain relief, the number of inhalations administered until pain relief was achieved, and whether the patient covered the hole in the inhaler during inhalation were recorded. It was noted whether or not the patient requested rescue medication, and if applicable, the time of request for rescue medication. Prior to ED discharge, the patient, the treating physician and the research nurse completed an assessment of GMP measured using a 5-point Likert scale ('Poor', 'Fair', 'Good', 'Very Good', or 'Excellent').
Safety Assessments
Patients were monitored by a research nurse for the duration of the ED visit and any adverse events, not related to the trauma presentation, were recorded from the time of consent until the time of ED discharge. Information on any adverse events occurring during the follow-up period was collected at the 14 ± 2 day follow-up visit. For each adverse event, the investigator provided a 'Yes/No' assessment as to whether there was a reasonable possibility that the event may have been caused by methoxyflurane and evaluated its severity according to the National Cancer Institute Common Toxicity Criteria where applicable.
Vital signs (blood pressure, heart rate and rhythm, and respiratory rate) were assessed at enrollment and at 5, 10, 15, 20 and 30 min after the start of study medication inhalation and every 30 min thereafter until rescue medication was administered or discharged from the ED, whichever was sooner. Level of consciousness was measured using the 15-point Glasgow coma score at 10, 20 and 30 min after the start of study medication inhalation and prior to ED discharge. Blood samples were drawn for clinical laboratory tests (complete blood count and clinical chemistry including blood glucose, sodium, potassium, calcium, chloride, serum creatinine, alanine transaminase, aspartate transaminase, gamma-glutamyl transferase, alkaline phosphatase, lactate dehydrogenase, total bilirubin, blood urea nitrogen, albumin and total protein) within -10 to ?5 min of the start of study medication inhalation and at the 14 ± 2 day follow-up visit.
Statistical Analyses
The primary efficacy endpoint was the change in pain intensity as measured using the VAS scale from baseline to 5, 10, 15 and 20 min after the start of study medication inhalation, which was analyzed using repeated measures analysis of covariance adjusted for baseline VAS score, and the interaction between time point and treatment. The primary analysis was the overall test for treatment effect considering all four time points. Treatment effects were estimated as least squares mean differences between the methoxyflurane group and the placebo group. Use of rescue medication within 20 min of the start of treatment (yes/no) was compared using logistic regression. The assessment of the GMP by the patient, research nurse and treating physician were each compared between the treatment groups using ordinal logistic regression with proportional odds assumption.
All analyses were adjusted for baseline VAS scores (patients with no baseline VAS pain score were excluded from the analysis). Other efficacy endpoints were summarized descriptively.
All statistical analyses were performed using SAS Ò version 9.2 or higher (SAS Institute Inc., Cary, NC, USA). All hypothesis testing was carried out at the 5% (two-sided) significance level unless stated otherwise. There was no imputation of missing data; if a baseline value was missing, no change from baseline was calculated. Baseline was defined as the last recorded value before the first dose. Efficacy analyses were performed using the intention-to-treat population, defined as all randomized patients who received at least one dose of study medication and had at least one post-baseline efficacy assessment. Safety presentations were descriptive and based on the safety population, which included all randomized patients who received at least one dose of study medication. Adverse events from enrollment to 14 ± 2 days after ED discharge were coded using the Medical Dictionary for Regulatory Activities (MedDRA version 14.0, McLean, VA, USA) coding system.
Events were classified as treatment-emergent if they started or increased in severity on or after the first date and time of study medication dosing.
Sample Size
The sample size calculation for the whole study including both adult and adolescent patients, estimated that 150 patients per arm would provide at least 94.5% power to detect a treatment difference of 13 mm [26] in change from baseline of VAS pain score after 20 min using repeated measures analysis of variance of assessments at 5, 10, 15 and 20 min. Given the setting of the study, the dropout rate was expected to be minimal, and a sample size of 150 patients per arm was considered adequate. The planned sample size was achieved in the full study population (300 patients were randomized); however, the study was not intended to be sufficiently powered to demonstrate a statistically significant treatment difference in the adult-only subgroup that we report here (102 patients in the methoxyflurane treatment group and 101 patients in the placebo group).
Compliance with Ethics Guidelines
The study was conducted in accordance with International Council on Harmonization Good 
RESULTS
Study Patients
Participant flow is shown in Fig. 1 . A total of 205 adult patients were screened; one patient failed screening because her second NRS score of 8 was outside the inclusion range, and the remaining 204 patients were randomized to double-blind treatment (103 patients to methoxyflurane and 101 patients to placebo). One patient in the methoxyflurane group discontinued due to an adverse event (light headed/hyperventilation) before receiving study treatment, therefore 203 patients were treated and analyzed for efficacy (intention-to-treat population) and safety. The majority of patients completed the study to Day 14 ± 2; however, 12 patients (11.7%) in the methoxyflurane group and 11 patients (10.9%) in the placebo group were lost to follow-up.
Demographic and baseline characteristics are presented in Table 1 and injuries due to foreign body were each reported for\5% of patients. Eleven patients had [1 injury, including two who had three injuries (second and third injury types included contusions, lacerations and 'other'). Mean baseline VAS pain intensity score was 66.2 mm in the methoxyflurane group and 65.5 mm in the placebo group, indicating that on average, patients were experiencing pain of at least moderate severity at baseline [27] . Overall, the two treatment groups were evenly matched with regard to patient demographic characteristics, injury type and baseline pain severity.
Efficacy
Methoxyflurane significantly reduced pain intensity compared with placebo. Table 2 shows that for the overall change from Received methoxyflurane (n=102)
• 1 paƟent withdrew due to an adverse event (light headed/hypervenƟlaƟon) before receiving study treatment
Allocated to placebo (n=101)
Received placebo (n=101)
Completed study to Day 14±2 (n=90)
Discontinued study (n=12)
• Lost to follow-up (n=12)
Discontinued study (n=11)
• Lost to follow-up (n=11)
Analyzed for efficacy (ITT, n=101)
Analyzed for safety (N=101)
Analyzed for efficacy (ITT, n=102)
Anayzed for safety (n=102) Fig. 1 Participant flow. NRS numerical rating scale, ITT intention-to-treat population. The ITT population is defined as those patients in the safety population who have at least one post-baseline efficacy assessment Table 4 ).
Approximately, three-quarters of patients, physicians and research nurses rated methoxyflurane treatment as 'Excellent', 'Very Good' or 'Good' (77.6% of patients, 74.5% of physicians and 72.5% of research nurses).
Inhaler Use
A total of 25 patients (24.5%) in the methoxyflurane group and 15 patients (14.9%) in the placebo group requested a second Significance of treatment effect was adjusted for baseline pain score 
DISCUSSION
The results of this study confirm that methoxyflurane is a highly effective analgesic for adult patients in the ED setting. There was a highly significant difference between the methoxyflurane and placebo groups (p\0.0001) in the analysis of the VAS pain intensity score at all-time points tested, despite a considerable 'placebo effect'. In a previous Although methoxyflurane is currently only licensed for emergency relief of pain due to trauma in Europe, several studies in Australia and New Zealand have also demonstrated its effectiveness as a procedural analgesic [21, [33] [34] [35] [36] .
The rate of treatment-related adverse events was higher with methoxyflurane (42.2%) than placebo (14.9%); this was mostly attributable to a higher incidence of dizziness/lightheadedness and headache in the methoxyflurane group, which are both adverse events already captured in the product label [13] . However, the majority of adverse events were mild and transient in nature, no patients discontinued use of methoxyflurane due to adverse events and patients rated their satisfaction with methoxyflurane treatment highly, (77.6% assessing treatment as 'Excellent', 'Very Good' or 'Good'). It should also be taken into account that study treatment exposure was higher in the methoxyflurane group than the placebo group; patients in the placebo group requested rescue medication significantly earlier than patients in the methoxyflurane group, and 24.5% of patients in the methoxyflurane group compared with 14.9% in the placebo group used a second inhaler. While this is unlikely to have affected the key efficacy endpoints, which mainly considered the early effects of study treatment (in the first 20 min), it may have had an impact on safety results. We also observed no effects of methoxyflurane on vital signs, which are consistent with the findings from two retrospective, observational studies of methoxyflurane analgesia in the pre-hospital setting that looked at records of 1217 patients treated by the Australian Ambulance Service [19, 37] .
In this study, although clinical laboratory sampling was limited, no evidence of nephroor hepatotoxicity was observed. Similarly, in patients receiving methoxyflurane as procedural analgesia for bone marrow biopsy, blood analysis of urea and electrolytes was no different between those patients receiving methoxyflurane and those receiving placebo [35] 
CONCLUSION
In conclusion, consistent with evidence from previous studies, the results of this study show that low-dose methoxyflurane administered via the Penthrox inhaler is an easy to use, well-tolerated, effective and rapid-acting analgesic in the ED setting. Considering its fast onset of action, ease of use and minimal impact on subsequent treatment choices, methoxyflurane may also lend itself as a bridging agent in the pre-hospital/ED setting until it is possible to administer more powerful analgesia if required, and also as a short-term procedural analgesic. 
ACKNOWLEDGMENTS
